Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

TKM-PLK1 · TKM-080301

Oligonucleotide (siRNA) · Gene silencing: polo-like kinase 1 (PLK1) · developed by Arbutus Biopharma

Phase 1/2 Most advanced trial (none active)
ABUS Developer
1 Registered trials

What is TKM-PLK1?

TKM-PLK1 is a lipid-encapsulated siRNA that binds PLK1 mRNA to inhibit translation and expression of polo-like kinase 1 protein. By blocking PLK1, it prevents tumor cell mitosis, causes cell cycle arrest and apoptosis. It is studied in hepatocellular carcinoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
TKM-080301, PLK1-HCC
Drug type
Oligonucleotide (siRNA)
Targets
polo-like kinase 1 (PLK1)
Mechanism
Gene silencing: polo-like kinase 1 (PLK1)
Pathways
cell cycle arrest, apoptosis
Therapy area
Oncology
Developer
Arbutus Biopharma Corporation (ABUS)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT02191878 Phase 1/2 Hepatocellular Carcinoma Completed ABUS

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Hepatocellular CarcinomaHepatomaLiver Cancer, AdultLiver Cell Carcinoma, Adult

More from Arbutus Biopharma

AB-836 Phase 1 ARB-001467 Phase 2 Imdusiran Phase 2 Peg-IFNα-2a Phase 2 PRO-040201 Phase 1 TKM-100201 Phase 1 TKM-100802 Phase 1

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the ABUS page.

Follow ABUS, the company behind TKM-PLK1

See ABUS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ABUS catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.